AstraZeneca PLC
[AZN]
NYSE
MVPro™ Score: 63/100
Last Earnings: 06 Nov 2025
[AZN]
NYSE
MVPro™ Score: 63/100
Last Earnings: 06 Nov 2025
Powered by AI
| Capitalization (mln USD) | 235,814 |
| Revenue (mln USD) | 14,457 |
| EBITDA (mln USD) | 4,897 |
| Net Income (mln USD) | 2,450 |
| Net Margin | 16.95% |
| EPS Ratio (TTM, USD) | 2.66 |
| P/E Ratio (TTM) | 28.41 |
| P/S Ratio (TTM) | 3.83 |
| D/E Ratio | 1.51 |
| EV/EBITDA (TTM) | 15.25 |
| CAPEX (Q/Q) | 98.45% |
| Dividend Yield | 1.98% |
Revenue, EBITDA & Net Income
Company Overview
AstraZeneca PLC is a multinational biopharmaceutical company headquartered in Cambridge, United Kingdom, with origins in the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group. Since then, the firm has become one of the world’s leading pharmaceutical players, building a strong reputation for innovation and global reach. Its history shows a consistent focus on advancing healthcare through pioneering research and development.
The company’s core activities include the discovery, development, and commercialisation of prescription medicines, with emphasis on oncology, cardiovascular, renal, respiratory, and rare diseases. Its recognised products include Tagrisso for lung cancer, Symbicort for asthma, and treatments for metabolic and immunological conditions. AstraZeneca also invests in biotechnology, vaccines, and next-generation therapies to reinforce its competitive position.
The group is currently led by Chief Executive Officer Pascal Soriot, who has guided its strategy since 2012. AstraZeneca operates across more than 100 countries, with especially strong positions in Europe, North America, and emerging markets such as China. Its mission is to push the boundaries of science to deliver life-changing medicines, and its ESG commitments are demonstrated through sustainability initiatives, equitable access to healthcare, and responsible business practices supporting long-term growth.
🟡 P/E (Price to Earnings, TTM)
Price-to-earnings (P/E) ratio for the most recent quarter is 26.1, compared to 29.3 in the previous quarter, with a longer-term trend value of 42.9. This decline in the P/E ratio may indicate a shift in market sentiment, where investors are placing a lower premium on future earnings growth. A falling P/E ratio could be driven by slowing revenue growth, increased risk perception, or improved earnings performance that is outpacing stock price growth.
P/E Ratio
Source: MarketVectors.Pro, AstraZeneca Financial Reports (TTM)
P/E Ratio
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Full Premium Plan.
Download now with your Full Premium Plan.
🟢 EPS (Earnings Per Share, TTM)
AstraZeneca's earnings per share (EPS) for the most recent quarter is 2.66 USD (+6.9%), compared to 2.49 USD in the previous quarter, with a longer-term trend value of 3.95 USD. This quarterly increase in EPS suggests improved profitability and operational efficiency.
EPS
Source: MarketVectors.Pro, AstraZeneca Financial Reports (TTM, USD)
EPS
📌 The full analysis and strategic conclusions for this section are exclusively available in our PDF reports.
Download now with your Full Premium Plan.
Download now with your Full Premium Plan.
Unlock the Power of Financial Intelligence
Built for everyday investors, professionals and everyone in between.
Start for Free – No Credit Card NeededBest for informed investors seeking deeper insights
Built for professionals and power users who want it all
Register for FREE Now
Disclaimer
This report is provided for informational purposes only and does not constitute financial, investment, legal, tax, or professional advice. The information, analyses, forecasts, and opinions contained herein are based on sources believed to be reliable as of the publication date. However, MarketVectors.Pro, its affiliates, officers, directors, employees, and agents make no warranties or representations, express or implied, regarding the accuracy, completeness, reliability, or suitability of this information for any particular purpose. The data, assumptions, and projections provided are subject to change without notice.
No Investment or Legal Advice
This report does not constitute an offer, recommendation, or solicitation to buy, sell, or hold any financial instrument, security, commodity, or investment. Any investment decisions made by the recipient are made entirely at their own discretion and risk. MarketVectors.Pro and its affiliates expressly disclaim any and all liability for investment losses, financial damages, or any other consequences arising from reliance on this report, whether such losses result from errors, omissions, misinterpretations, or unforeseen market conditions.
The recipient acknowledges and agrees that MarketVectors.Pro shall not be held liable under any legal theory, including but not limited to negligence, breach of fiduciary duty, or misrepresentation, for any direct, indirect, incidental, consequential, or punitive losses incurred. Furthermore, past performance is not indicative of future results, and no assurance or warranty is given regarding the accuracy, completeness, or reliability of the information contained herein. The recipient is strongly encouraged to seek independent professional advice before making any financial decisions.
This report may contain inaccuracies, errors, or omissions. MarketVectors.Pro and its affiliates expressly disclaim any responsibility for such inaccuracies and make no warranties, express or implied, regarding the correctness or completeness of the information provided. The recipient agrees not to hold MarketVectors.Pro liable for any such inaccuracies or their consequences.
Forward-Looking Statements and Risk Disclosures
This report may contain forward-looking statements based on assumptions, estimates, and expectations that are inherently subject to known and unknown risks and uncertainties. Actual results may differ materially from those projected due to factors beyond the control of MarketVectors.Pro, including but not limited to market fluctuations, geopolitical events, regulatory changes, and macroeconomic conditions. No assurances or guarantees can be made that any projections, expected returns, or forecasts will be realized.
Past performance is not indicative of future results. The recipient acknowledges that all forward-looking statements are inherently uncertain and that actual results may differ significantly from projections. MarketVectors.Pro does not guarantee any level of performance or return on investment.
Jurisdictional and Regulatory Considerations
This document is intended for recipients in jurisdictions where its distribution and access are legally permitted. It may not comply with regulatory standards in all jurisdictions and should not be used or relied upon in any jurisdiction where such distribution would violate local laws or regulations. Recipients are responsible for ensuring compliance with applicable local laws before engaging in any financial activities based on this report.
Confidentiality and Restriction on Distribution
This report is confidential and solely intended for the designated recipient. It may not be copied, reproduced, distributed, or shared without the prior written consent of MarketVectors.Pro. Unauthorized use or distribution of this document may be subject to legal action under applicable intellectual property and confidentiality laws.
Limitation of Liability
To the fullest extent permitted by law, MarketVectors.Pro, its affiliates, officers, directors, employees, and representatives expressly disclaim any and all liability for any damages or losses, whether direct, indirect, incidental, consequential, punitive, or otherwise, arising from the use or reliance on this report.
By accessing or using this report, the recipient acknowledges and agrees to the above terms and waives any claims against MarketVectors.Pro and its affiliates related to the content, analysis, or recommendations provided.
